Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Thoracic 1

Conditions

Nasopharyngeal Carcinoma 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Melanoma 2Endometrial Neoplasms 2Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharangeal Cancer 1Lymphoma, T-Cell, Peripheral 1Lung Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Squamous Cell Carcinoma 1Diffuse Intrinsic Pontine Glioma 1CRC 1

Interventions

Cisplatin 18Gemcitabine 14Radiotherapy, Intensity-Modulated 11Magnetic Resonance Spectroscopy 8toripalimab 7Specimen Handling 7Capecitabine 7Platinum 5Drug Therapy 51,2-diaminocyclohexaneplatinum II citrate 5camrelizumab 4Radiotherapy 4Nivolumab 4spartalizumab 3sintilimab 3anlotinib 3Immunoglobulin G 3Immune Checkpoint Inhibitors 3Docetaxel 3Disulfides 3atezolizumab 2Radiation 2Phantoms, Imaging 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2Biopsy 2Bevacizumab 218-O-demethylcervinomycin A2 2tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × spartalizumab × 90 days × Clear all
NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 1/2 Recruiting
148 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT05201859 2026-05-07

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Active not recruiting
150 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06475300 2026-05-06

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
570 enrolled
Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡